← All Oculis Holding AG filings

Oculis Holding AG 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
OCS
Oculis Holding AG
20-F: Oculis Secures Upsized Loan, Advances Key Clinical Programs
Oculis Holding AG reports an upsized loan facility of up to CHF 75 million and significant progress in its clinical pipeline, including expected topline results for OCS-01 and Licaminlimab in 2026.
NASDAQ
OCS
Oculis Holding AG
20-F: Oculis Holding AG Releases 2024 Financial Results and Provides Business Update
Oculis Holding AG reports its financial results for the year ended December 31, 2024, highlighting key developments in its clinical programs and strategic initiatives.
NASDAQ
OCS
Oculis Holding AG
20-F: Oculis Holding AG Releases 2023 Financial Results in Form 20-F Filing
Oculis Holding AG reports its financial performance for the year ended December 31, 2023, in its annual Form 20-F filing, detailing net losses and strategic developments.